Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Johnson & Johnson

Sanofi

Sometimes, the huge potential gains of small biotechs are worth the risk.

These 3 Stocks Will Make You A Fortune If They Succeed

Vaxart stock has declined by around 25% over the last month and currently trades at about $5.80 per share. While the recent sell-off in the clinical stage biotech is due to broader correction in technology and biotech names, Vaxart stock has come under pressure since early February when the company.

Vaxart Stock Should Rebound After 25% Decline Over The Last Month

What Are the Prospects for Vaxart's COVID Vaccine?

Inovio Pharmaceuticals

Let's look at what some of the smartest investors are saying.

Vaxart or Inovio: Which Is More Likely to Double Your Money?

Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06.  The stock was trending on StockTwits, and there was no company evident news to explain the volume increase.

Vaxart Stock Trades Higher On Increased Volume: A Technical Analysis

Novavax

Ocugen, Inc.

Each of these players has dropped about 40% or more in recent weeks.

Should You Buy These Vaccine Stocks After the Sell-Off?

If its oral vaccine technology comes to fruition, then answering that question is easy.

Could Vaxart Be a Warren Buffett Stock?

Vaxart stock dropped 16% over the last five trading days, significantly underperforming the S&P 500 which gained about 1% over the same period. The stock is also down by about 40% over the last month (twenty-one trading days), although it remains up by 5% year-to-date.

Is Vaxart Stock Worth A Look After 40% Decline Over The Last Month?

A flaw in the logic behind a big sell-off may lead to a big surprise sometime in 2021.

Where Will Vaxart Be in 1 Year?

The clinical-stage vaccine-focused biotech recently offered investors a glimmer of hope about its COVID-19 candidate.

Should You Buy Vaxart Stock in March?

Vaxart's trial data disappointed -- but one bright spot could turn things around.

Can This 1 Element Keep Vaxart in the Coronavirus Vaccine Race?

Pfizer

And let's take a look at the most overrated, the most promising, and the most under-the-radar coronavirus stocks too.

This Is the Cheapest Coronavirus Vaccine Stock Right Now

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021.

Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference

There are plenty of entrants in the race to develop a Covid-19 vaccine, but distinct advantages mark VXRT stock as a worthy biotech holding. The post Vaxart Stock Remains a Buy as Unique Covid-19 Vaccine Is Developed appeared first on InvestorPlace.

Vaxart Stock Remains a Buy as Unique Covid-19 Vaccine Is Developed

VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume.

VAXART, INC. (VXRT) Moves 5.6% Higher: Will This Strength Last?

Vaxart stock (NASDAQ: VXRT) dropped -8% over the last five trading days and has underperformed the S&P 500 which remained roughly flat over the same period. The stock is also down by about -27% over the last month (twenty-one trading days), although it remains up by 29% year-to-date.

Is Vaxart Stock Set To Decline Further?

Could Vaxart Be a Millionaire-Maker Stock?

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021.

Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021

Let's look at what short-sellers are saying and what science is saying.

How Risky Is Vaxart?

In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.

VAXART, INC. (VXRT) Stock Sinks As Market Gains: What You Should Know

VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.

VAXART, INC. (VXRT) Dips More Than Broader Markets: What You Should Know

On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

News for Vaxart Stock (VXRT)